Advancing science has created exciting and very promising new approaches to cancer treatment. To assure the proper risk-benefit assessment of these new approaches, the IRB members must possess a deep understanding of the underlying science and clinical aspects of the associated treatments. Through WCG Oncology™, we provide our clients with the confidence that reviews will be conducted with the appropriate expertise and therapeutic focus.
Nearly 14 million people around the world learn that they have cancer every year. Another 8 million people die from the disease (according to the Centers for Disease Control). To help in the mission to find a cure, the WIRB-Copernicus Group® (WCG) has created WCG Oncology, a comprehensive solution to enable the highest quality review of cancer research and to ensure the safety of its participants.
WCG Oncology combines our unmatched expertise in regulatory and ethical oversight with the insights of the leaders in oncology research to deliver a precise, thorough review of clinical trials in oncology. WCG Oncology is comprised of:
George Demetri, MD
Dana-Farber Cancer Institute
John M. Falletta, MD
Duke University Medical Center
Arnold J. Levine, PhD
Institute for Advanced Study, School of Natural Sciences
John E. Niederhuber, MD
Inova Translational Medicine Institute;
James Rothman, PhD
Yale University; Recipient, Nobel Prize in Medicine, 2013
Howard Scher, MD
Memorial Sloan Kettering Cancer Center
Currently, WCG oversees more than 1,000 oncology research protocols at over 4,000 sites across the United States, including many of the leading academic medical centers, research hospitals and universities. Together with our partners in oncology research and cancer care, we will accelerate advancements in oncology research and – one day – find a cure.
WCG Oncology Reggie Scott